



Polymer Factory Sweden (publ) Interim report Q2 2025

Second quarter, April-June 2025

- Earnings increased by 87% during the quarter compared to Q2 2024
- Polymer Factory announces a substantial order of SpheriCal® products
- The company signed a Supply Agreement with Global Leader in Scientific Instrumentation
- Polymer Factory Receives Order from International Energy Company
- Bruker launches QSee™ in partnership with Polymer Factory

Comments from CEO Mats Wallnér

During the second quarter of 2025, we saw improved financial balance in the company – revenues increased significantly while costs were reduced. This is a sign of strength and indicates that the initiatives we have taken are starting to yield results.

“Net sales increase by +358% in Q2-2025”

Polymer Factory Signs Supply Agreement with Bruker

Polymer Factory has signed a supply agreement with Bruker, a global leader in scientific instrumentation. Bruker recently launched QSee™, a suite of software and reference materials for automated quality control of instrument performance, including long-term monitoring via the cloud-based TwinScape™ platform. In partnership with Polymer Factory, the leading manufacturer of stable polymer-based calibrants for mass spectrometry, the SpheriCal® platform has been expanded to include the new QSee™ 8-mix, enabling comprehensive evaluation of chromatographic and mass spectrometric performance.

Financial Development – Q2 2025

It is highly encouraging that net sales increased by +358% in Q2 2025 compared to the same quarter in 2024. At the same time, the company's costs were reduced by 27%, resulting in a +87% improvement in earnings compared to Q2 2024. Of particular note is that sales of SpheriCal® increased by approximately 740% year-over-year – a strong indication of rising demand and market acceptance.

Our Customers

Polymer Factory's customers include global industry leaders, clinical institutions, and several of the world's top-ranked universities. We are proud that these organizations have discovered our products and recognize the significant value we offer. During Q2 2025, Polymer Factory completed around 20 customer transactions through both e-commerce and invoiced sales. Virtually all product sales were made to customers in North America and Europe, outside of Sweden.

Targeting Positive Cash Flow and Profitability

During the quarter, Polymer Factory took further steps to proactively and systematically approach potential customers where our products offer high value. In addition, cost structure adjustments are being implemented, including increased use of commission-based compensation models. The company's clear goal is to achieve positive cash flow and profitability in the near term.

Global Uncertainty, Local Resilience

As is widely recognized, the global environment remains turbulent, and there is growing concern about continued access to the critically important U.S. market. So far, the ongoing trade conflict has not had a noticeable impact on our operations. Despite the global uncertainty, I remain confident in Polymer Factory's progress throughout 2025. Our commercial partners appreciate the customer value our products deliver, as well as the deep expertise and technical knowledge that resides within the company.

This disclosure contains information that Polymer Factory is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 15-08-2025 08:00 CET.

For more information, please contact:

Mats Wallner, Acting CEO

Phone: +46 (0) 70 951 95 06

E-mail: mats.wallner@polymerfactory.com

Polymer Factory (publ) is a leading global provider and producer of dendritic materials, with customers ranging from BigPharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. The Company's dendritic materials act as smart delivery systems that enhance the effects of the substances they carry, e.g. a vaccine or an anticancer drug. They have also shown great promise in diagnostics, tissue engineering and in the development of vaccines. In addition, Polymer Factory has used the Company's vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments. The Company's dendritic nanotechnologies have the potential to accelerate innovation in technologically demanding sectors, such as MedTech and BioTech. Learn more at www.polymerfactory.com.